The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis
PLOS Pathogens · 2024
DOI: 10.1371/journal.ppat.1012343 ↗Kurz gefasst
Fachartikel in der Zeitschrift PLOS Pathogens, 2024. Verfasst von Trevor Griesman und 11 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia Pennsylvania, United States of America. Hauptthemen laut MEDLINE: Rift Valley fever virus, Lipopeptides, Rift Valley Fever, Neurons. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 85 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIAID NIH HHS, Intramural NIH HHS, Division of Intramural Research, National Institute of Allergy and Infectious Diseases.
Abstract (Originalsprache)
Rift Valley fever virus (RVFV) is an encephalitic bunyavirus that can infect neurons in the brain. There are no approved therapeutics that can protect from RVFV encephalitis. Innate immunity, the first line of defense against infection, canonically antagonizes viruses through interferon signaling. We found that interferons did not efficiently protect primary cortical neurons from RVFV, unlike other cell types. To identify alternative neuronal antiviral pathways, we screened innate immune ligands and discovered that the TLR2 ligand Pam 3 CSK 4 inhibited RVFV infection, and other bunyaviruses. Mechanistically, we found that Pam 3 CSK 4 blocks viral fusion, independent of TLR2. In a mouse model of RVFV encephalitis, Pam 3 CSK 4 treatment protected animals from infection and mortality. Overall, Pam 3 CSK 4 is a bunyavirus fusion inhibitor active in primary neurons and the brain, representing a new approach toward the development of treatments for encephalitic bunyavirus infections.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Pathology and Laboratory Medicine, University of Pennsylvania, Philadelphia Pennsylvania, United States of America.
- Center for Vaccine Research, University of Pittsburgh, Pittsburgh, Pennsylvania, United States of America.
- Department of Infectious Diseases and Microbiology, University of Pittsburgh School of Public Health, Pittsburgh, Pennsylvania, United States of America.
- Department of Microbiology, University of Pennsylvania, Philadelphia Pennsylvania, Unites States of America.
- High throughput screening core, University of Pennsylvania, Philadelphia, Pennsylvania, United States of America.
ORCID-Profile: Sara Cherry
Förderung
- NIAID NIH HHS
- Intramural NIH HHS
- Division of Intramural Research, National Institute of Allergy and Infectious Diseases
- Burroughs Wellcome Fund
Zitieren
APA
Griesman, T., McMillen, C. M., Negatu, S. G., Hulahan, J. J., Whig, K., Dohnalová, L., Dittmar, M., Thaiss, C. A., Jurado, K. A., Schultz, D. C., Hartman, A. L., & Cherry, S. (2024). The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis. PLOS Pathogens. https://doi.org/10.1371/journal.ppat.1012343
Vancouver
Griesman T, McMillen CM, Negatu SG, Hulahan JJ, Whig K, Dohnalová L, et al. The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis. PLOS Pathogens. 2024. doi:10.1371/journal.ppat.1012343
BibTeX
@article{Griesman2024,
author = {Griesman, Trevor and McMillen, Cynthia M and Negatu, Seble Getenet and Hulahan, Jesse J and Whig, Kanupriya and Dohnalová, Lenka and Dittmar, Mark and Thaiss, Christoph A and Jurado, Kellie A and Schultz, David C and Hartman, Amy L and Cherry, Sara},
title = {The lipopeptide Pam3CSK4 inhibits Rift Valley fever virus infection and protects from encephalitis},
journal = {PLOS Pathogens},
year = {2024},
doi = {10.1371/journal.ppat.1012343}
}
EUVIMED